Biochemical treatment of precancerous oral lesions: the effectiveness of various analogues of retinoic acid.
Leukoplakia is neither a clinical, aetiological nor histopathological entity. Therefore treatment is difficult particularly in multifocal and advanced lesions. Since 1970, we have tested the therapeutic effect of different derivatives of all-trans-retinoic acid. The study includes 75 cases with homogeneous leukoplakia without or with minimal epithelial dysplasia. Over 60% of the cases treated showed positive early results. In follow-ups from 1 to 6 years about 45% of cases showed complete or partial remission. The rest showed relapses or even progression. In cases with recurrence without changes in the morphological characteristics, positive effects were achieved with 1 to 4 repeated courses of therapy. All derivatives of retinoic acid tested so far have shown undesirable side effects with systematic manifestations or local symptoms: interruption of treatment (4) or reduction of dosage (9) were unavoidable for that reason. Regarding the side effects, retinoic acid should only be given under clinical supervision. Of the derivates tested to date, aromatic retinoid seems to have the best curative potential in homogenic leukoplakia.
D006801:Humans; D007972:Leukoplakia, Oral / Q000188:drug therapy*; D009062:Mouth Neoplasms / Q000188:drug therapy*; D011230:Precancerous Conditions / Q000188:drug therapy*; D012008:Recurrence; D014212:Tretinoin / Q000627:therapeutic use*; D014801:Vitamin A / Q000031:analogs & derivatives* / Q000627:therapeutic use
D014801:Vitamin A; D014212:Tretinoin